| Name | Title | Contact Details |
|---|
We understand that mental health needs often increase in times of uncertainty. Concerned? Please reach out. CHC is currently accepting new referrals.
Blue Cross and Blue Shield Plans in Illinois, Montana, New Mexico, Oklahoma, Texas and several subsidiaries are part of the largest customer-owned health benefits company in the United States and fourth largest overall. We offer a full range of managed care programs for individuals, families, employer groups and Medicare beneficiaries. And we focus on improving the health and wellness of our members and communities by: • offering a variety of health insurance and wellness products to employers and individuals • keeping our focus local • participating in our communities in meaningful ways such as Blue Corps employee volunteer program and our Healthy Kids, Healthy Families initiative The commitment of our employees to providing superior services and products has made us one of the fastest growing health care insurance companies in the nation. Blue Cross and Blue Shield of Illinois Blue Cross and Blue Shield of Montana Blue Cross and BlueShield of New Mexico Blue Cross and Blue Shield of Oklahoma Blue Cross and Blue Shield of Texas Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. We are an Equal Opportunity Employment / Affirmative Action employer dedicated to workforce diversity and a drug-free and smoke-free workplace. Drug screening and background investigation are required, as allowed by law. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, national origin, disability, or protected veteran status.
AutoCruitment is a metrics-driven ecosystem of patient recruitment and engagement solutions, digitizing and revolutionizing the end-to-end patient and client experience. Our multifaceted approach utilizes sophisticated algorithms, advanced automation, and over 1,500 direct-to-patient online channels to find, screen, and automatically refer highly qualified patients with a greater chance of randomization success. The results are higher enrollment and greater patient engagement, accelerating timelines and exceeding milestones at every phase of clinical research. The AutoCruitment Difference: •Targeted: The AutoCruitment platform`s proprietary algorithms and innovative approach help precisely target your ideal patient population, reaching over 247 million patients to date •Experienced: AutoCruitment has completed over 578 studies and has a continuously learning and growing database of over 10 million patients •Technology-Enabled: The AutoCruitment platform utilizes advanced online screeners to simultaneously screen for multiple studies and provide customized cohort volumes based on your project`s needs •Volume- and Quality-Focused: The far-reaching power of the AutoCruitment platform and our direct-to-patient methodology excels at attracting and retaining optimal volumes of highly qualified patients •Transparent: The AutoCruitment portal and its robust reporting capabilities enable complete and real-time transparency from the very beginning •Metrics-Driven: Our patient recruitment scientists work in complete collaboration with your study teams and research sites to optimize the program and increase randomization by an average of 97% per month AutoCruitment delivers something different. Our comprehensive ecosystem of scalable solutions offers a 3-day startup time and swiftly removes the recruitment barrier for biotech innovations and pharmaceutical research, shortening timelines and trimming budgets for a quicker, smoother path to market.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.